| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst Jonathan Block reinstates Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and announces $15 price target.
Truist Securities analyst Richard Newitter maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Hold and raises the price tar...
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target fro...
Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Buy and maintains $24 price ...
Tandem Diabetes Care, Inc.
This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and...
Mad Money's Jim Cramer looks at Phillips 66 and Intuitive Surgical, as well as Tandem Diabetes Care and Cintas.